ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab,Lenalidomide,Idecabtagene vicleucel,Ixazomib,Carfilzomib,Elotuzumab
Janssen,BMS,2Seventy Bio,takeda,AbbVie
['mmsm']
conclusion: #mmsm #asco2023 
Multiple Myeloma Specialist  at UTSW Harold C. Simmons Comprehensive Cancer Center | Montefiore  & Tufts Alum